INCB 098377
Alternative Names: INCB-098377Latest Information Update: 31 May 2023
Price :
$50 *
At a glance
- Originator Incyte Corporation
- Class Antineoplastics
- Mechanism of Action Phosphatidylinositol 3 kinase gamma inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 14 Apr 2023 Preclinical trials in Cancer in USA (unspecified route)
- 14 Apr 2023 Pharmacodynamics data from a preclinical study in Cancer presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
- 14 Mar 2023 Early research development in Cancer in USA (unspecified route)